Meet our Ambassador: Amar Latif
Amar Latif is an adventurer, entrepreneur, TV presenter and public speaker. He became an Ambassador for Retina UK in 2020.
Search
Search results
Meet our Ambassador: Steve Bate MBE
Steve is a Paralympian who was diagnosed with retinitis pigmentosa (RP) in 2011.
Meet our Ambassador: Bhavini Makwana
Her work with us enables her to achieve her aim of empowering others living with similar conditions to her own.
Meet our community: Simon Lakin
Simon talks about his experience of genetic testing and counselling.
ProQR clinical trial for Leber’s Congenital Amourosis (LCA) 10
Biopharmaceutical company ProQR is conducting a Phase 2/3 clinical trial (Illuminate) to measure the safety and effectiveness of RNA therapy, Sepofarsen which aims to treat Leber's Congenital Amourosis (LCA) 10.
Why genes matter
Genes exist inside all the cells that make up your body. They contain genetic code (DNA) and provide instructions for constructing proteins, which are the building blocks of our bodies and perform a huge variety of roles.
Meira GTx announces positive data from phase clinical trial
Biotechnology company MeiraGTx has announced encouraging news from its phase 1/2 clinical trial of botaretigene sparoparvovec (previously known as AAV-RPGR), a gene therapy aimed at X-linked retinitis pigmentosa caused by faults in the RPGR gene.
Frequently asked questions
The following questions are often asked by people contacting Retina UK.
Fundraising FAQs
Fancy fundraising for Retina UK? Here’s a few pointers to help get you started.
Positive early findings from ProQR trial of USH2A therapy
Biotechnology company ProQR has announced encouraging results from its early analysis of the phase 1/2 trial of QR-421a, an innovative approach to treating sight loss caused by mutations in a particular section of the USH2A gene.